Centessa Pharmaceuticals Files 10-Q/A for Q2 2024
Ticker: CNTA · Form: 10-Q/A · Filed: Oct 18, 2024 · CIK: 1847903
| Field | Detail |
|---|---|
| Company | Centessa Pharmaceuticals PLC (CNTA) |
| Form Type | 10-Q/A |
| Filed Date | Oct 18, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q/A, amendment, quarterly-report
TL;DR
Centessa filed an amended Q2 10-Q. Check for updates.
AI Summary
Centessa Pharmaceuticals plc filed an amendment (10-Q/A) on October 18, 2024, for the quarterly period ended June 30, 2024. The filing pertains to their operations and financial status as of that date. The company is incorporated in England and Wales and operates within the Pharmaceutical Preparations sector.
Why It Matters
This amended filing provides updated financial and operational details for Centessa Pharmaceuticals for the second quarter of 2024, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This is a routine amendment to a quarterly report, not indicating new material adverse events.
Key Players & Entities
- Centessa Pharmaceuticals plc (company) — Filer of the 10-Q/A
- June 30, 2024 (date) — Quarterly period end date
- October 18, 2024 (date) — Filing date of the amendment
- England and Wales (location) — Jurisdiction of incorporation
FAQ
What is the purpose of this 10-Q/A filing?
This filing is an amendment (Amendment No. 1) to the quarterly report for the period ended June 30, 2024, filed by Centessa Pharmaceuticals plc.
What is the reporting period for this filing?
The quarterly period ended June 30, 2024.
When was this amended filing submitted?
The filing was submitted on October 18, 2024.
Where is Centessa Pharmaceuticals plc incorporated?
Centessa Pharmaceuticals plc is incorporated in England and Wales.
What is the SIC code for Centessa Pharmaceuticals plc?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,151 words · 5 min read · ~4 pages · Grade level 11.1 · Accepted 2024-10-18 16:01:01
Filing Documents
- d825263d10qa.htm (10-Q/A) — 49KB
- d825263dex311.htm (EX-31.1) — 7KB
- d825263dex312.htm (EX-31.2) — 7KB
- 0001193125-24-239617.txt ( ) — 259KB
- cnta-20240630.xsd (EX-101.SCH) — 5KB
- cnta-20240630_cal.xml (EX-101.CAL) — 1KB
- cnta-20240630_def.xml (EX-101.DEF) — 16KB
- cnta-20240630_lab.xml (EX-101.LAB) — 22KB
- cnta-20240630_pre.xml (EX-101.PRE) — 17KB
- d825263d10qa_htm.xml (XML) — 7KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CENTESSA PHARMACEUTICALS PLC Date: October 18, 2024 By: /s/ Saurabh Saha, M.D., Ph.D. Name: Saurabh Saha, M.D., Ph.D. Title: Chief Executive Officer (Principal Executive Officer) Date: October 18, 2024 By: /s/ John Crowley Name: John Crowley Title: Chief Financial Officer (Principal Financial Officer) 5